Long-Term Outcome of Immunosuppressive Therapy for Japanese Patients With Lower-Risk Myelodysplastic Syndromes

International Journal of Hematology - Japan
doi 10.1007/s12185-013-1468-8
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Long-Term Outcome of Anemic Lower-Risk Myelodysplastic Syndromes Without 5q Deletion Refractory to or Relapsing After Erythropoiesis-Stimulating Agents

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2013English

Romiplostim Monotherapy in Thrombocytopenic Patients With Myelodysplastic Syndromes: Long-Term Safety and Efficacy

British Journal of Haematology
Hematology
2017English

Relationship of Treatment-Related Cytopenias and Response to Lenalidomide in Patients With Lower-Risk Myelodysplastic Syndromes

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2008English

Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2012English

Androgen Therapy for Patients With Lower-Risk Myelodysplastic Syndrome and Significant Cytopenia: A Retrospective Study

British Journal of Haematology
Hematology
2019English

Improving Prognostic Tools for Patients With Myelodysplastic Syndromes

Mayo Clinic Proceedings
Medicine
2018English

Lenalidomide: Targeted Anemia Therapy for Myelodysplastic Syndromes

Cancer Control
MedicineOncologyHematology
2006English

Hematologic Responses to Deferasirox Therapy in Transfusion-Dependent Patients With Myelodysplastic Syndromes

Haematologica
Hematology
2012English

Deferasirox Therapy Is Associated With Reduced Mortality Risk in a Medicare Population With Myelodysplastic Syndromes

Journal of Comparative Effectiveness Research
Health Policy
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy